Julian Harrison
Stock Analyst at BTIG
(2.30)
# 1,415
Out of 4,667 analysts
36
Total ratings
50%
Success rate
-1.6%
Average return
Main Sectors:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACRS Aclaris Therapeutics | Upgrades: Buy | $8 | $3.96 | +102.02% | 4 | Nov 19, 2024 | |
| VYNE VYNE Therapeutics | Initiates: Buy | $8 | $2.82 | +183.69% | 1 | Nov 18, 2024 | |
| OTLK Outlook Therapeutics | Reiterates: Buy | $50 | $5.28 | +846.97% | 4 | Oct 18, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $56 → $61 | $19.79 | +208.24% | 3 | Sep 26, 2024 | |
| RZLT Rezolute | Maintains: Buy | $13 → $15 | $5.01 | +199.40% | 2 | Sep 10, 2024 | |
| LQDA Liquidia | Maintains: Buy | $29 → $25 | $10.12 | +147.04% | 3 | Aug 20, 2024 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $41 → $51 | $40.65 | +25.46% | 2 | Jul 24, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: Neutral | n/a | $2.66 | - | 4 | Jun 17, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Buy | $43 | $8.86 | +385.33% | 1 | May 20, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Buy | $32 → $40 | $27.50 | +45.45% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $9.97 | +110.63% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $55 | $20.31 | +170.80% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $45.04 | -4.53% | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $4 | $1.79 | +123.46% | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $0.54 | +27,677.78% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $49.82 | -27.74% | 1 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $105 | $54.14 | +93.94% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $364.33 | - | 2 | Feb 11, 2022 |
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $3.96
Upside: +102.02%
VYNE Therapeutics
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $2.82
Upside: +183.69%
Outlook Therapeutics
Oct 18, 2024
Reiterates: Buy
Price Target: $50
Current: $5.28
Upside: +846.97%
Viridian Therapeutics
Sep 26, 2024
Maintains: Buy
Price Target: $56 → $61
Current: $19.79
Upside: +208.24%
Rezolute
Sep 10, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $5.01
Upside: +199.40%
Liquidia
Aug 20, 2024
Maintains: Buy
Price Target: $29 → $25
Current: $10.12
Upside: +147.04%
Protagonist Therapeutics
Jul 24, 2024
Maintains: Buy
Price Target: $41 → $51
Current: $40.65
Upside: +25.46%
Aerovate Therapeutics
Jun 17, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.66
Upside: -
ABIVAX Société Anonyme
May 20, 2024
Initiates: Buy
Price Target: $43
Current: $8.86
Upside: +385.33%
Spyre Therapeutics
May 10, 2024
Maintains: Buy
Price Target: $32 → $40
Current: $27.50
Upside: +45.45%
Apr 12, 2024
Initiates: Buy
Price Target: $21
Current: $9.97
Upside: +110.63%
Feb 26, 2024
Initiates: Buy
Price Target: $55
Current: $20.31
Upside: +170.80%
Dec 20, 2023
Initiates: Buy
Price Target: $43
Current: $45.04
Upside: -4.53%
Nov 29, 2023
Assumes: Buy
Price Target: $4
Current: $1.79
Upside: +123.46%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $0.54
Upside: +27,677.78%
Mar 9, 2023
Initiates: Buy
Price Target: $36
Current: $49.82
Upside: -27.74%
Dec 13, 2022
Maintains: Buy
Price Target: $95 → $105
Current: $54.14
Upside: +93.94%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $364.33
Upside: -